Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Retained Earnings: 2013-2025

Historic Retained Earnings for Coherus Oncology (CHRS) over the last 11 years, with Sep 2025 value amounting to -$1.3 billion.

  • Coherus Oncology's Retained Earnings rose 10.33% to -$1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 billion, marking a year-over-year increase of 10.33%. This contributed to the annual value of -$1.6 billion for FY2024, which is 1.80% up from last year.
  • Latest data reveals that Coherus Oncology reported Retained Earnings of -$1.3 billion as of Q3 2025, which was down 2.71% from -$1.3 billion recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Retained Earnings ranged from a high of -$935.7 million in Q1 2021 and a low of -$1.6 billion during Q1 2025.
  • For the 3-year period, Coherus Oncology's Retained Earnings averaged around -$1.5 billion, with its median value being -$1.5 billion (2024).
  • Its Retained Earnings has fluctuated over the past 5 years, first slumped by 37.64% in 2021, then climbed by 12.07% in 2025.
  • Over the past 5 years, Coherus Oncology's Retained Earnings (Quarterly) stood at -$1.0 billion in 2021, then decreased by 27.79% to -$1.3 billion in 2022, then declined by 17.73% to -$1.6 billion in 2023, then climbed by 1.80% to -$1.6 billion in 2024, then increased by 10.33% to -$1.3 billion in 2025.
  • Its last three reported values are -$1.3 billion in Q3 2025, -$1.3 billion for Q2 2025, and -$1.6 billion during Q1 2025.